NCT00596804 2021-08-18
Safety Study of Different Doses of hA20 (Veltuzumab) in CD20+ Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 1/2 Completed
Clinical Trials
6 trialsNCT00285428 2021-08-17
Study of hA20 (Humanized Anti-CD20) in Patients With CD20+ Non-Hodgkin's Lymphoma
Gilead Sciences
Phase 1/2 Completed
NCT00546793 2021-08-16
Ph I/II Study of Subcutaneously Administered Veltuzumab (hA20) in NHL and CLL
Gilead Sciences
Phase 1/2 Completed
NCT01147393 2018-02-22
Combination Veltuzumab and Fractionated 90Y- Epratuzumab Radioimmunotherapy in Follicular Lymphoma
Weill Medical College of Cornell University
Phase 1/2 Terminated
NCT01390545 2016-04-13
VELVET
Takeda
Phase 2 Terminated
NCT01279707 2014-07-14
MARALL
Queen Mary University of London
Phase 1/2 Unknown